DOCSLIB.ORG

Polyphenols Stilbenoids Flavonoids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Polyphenols Stilbenoids Flavonoids Polyphenols Stilbenoids Flavonoids OH OCH3 O CH3O HO OCH3 CH3O O OH OCH3 Resveratrol 1g / 5g / 25g [R0071] OCH3 Antioxidant, COX inhibitory, PPAR activation, SIRT1 (longevity gene) activation Reference Biol. Pharm. Bull. 2012, 35, 273. Nobiletin 10mg / 100mg [N0871] Carcinogenesis inhibitory, Antioxidant, Anti-inflammatory, Anti-dementia effect OH Reference J. Funct. Foods. 2014, 6, 2. HO OH Apigenin 100mg [A1514] Baicalin 25g [B2835] Baicalein 1g / 5g [T2721] HO Chrysin 25g [C1652] Piceatannol 100mg / 1g [P1928] Dihydromyricetin 200mg / 1g [D5464] Antioxidant, Antitumor, Anti-aging 3,4'-Dihydroxyflavone 1g / 5g [D4279] Reference Mutat. Res. Rev. Mutat. Res. 2012, 750, 60; Nature 2003, 425, 191. 7,8-Dihydroxyflavone Hydrate 1g / 5g [D1916] Diosmin 5g / 25g [D3908] OCH 3 Epmedin C 10mg / 50mg [E1320] Fisetin 100mg / 1g / 5g [T0121] Flavone 1g / 5g [F0015] HO Flavanone 5g / 25g [F0255] OCH3 Hesperetin 5g / 25g [H0721] Pterostilbene 100mg / 1g [P1924] Hesperidin 25g / 100g / 500g [H0049] Antioxidant, Antitumor 3-Hydroxyflavone 1g / 10g [H0379] Reference J. Surg. Res. 2012, 35, 273. 5-Hydroxyflavone 1g [H1238] Combretastatin A4 25mg / 250mg [C2520] 6-Hydroxyflavone 1g / 5g [H0851] Gnetol 100mg [G0371] 7-Hydroxyflavone 1g / 5g [H0852] Isorhapontigenin 100mg [I0804] 6-Hydroxyflavanone 1g / 5g [H1027] Oxyresveratrol 100mg / 1g [O0373] 7-Hydroxyflavanone 1g / 5g [H1006] Piceid 1g / 5g [P1878] 2'-Hydroxyflavanone 1g [H1024] Pinostilbene 100mg [P1927] 3'-Hydroxyflavanone 1g [H1025] Rhapontigenin 100mg [R0089] 4'-Hydroxyflavanone 1g [H1026] 3,4',5-Trimethoxy-trans-stilbene 5g [T1829] 3-Hydroxy-4'-methoxyflavone 1g / 5g [H1405] 3,3',4,5'-Tetramethoxypiceatannol 1g / 5g [T2842] Icariin 200mg / 1g [I0862] Isoxanthohumol 10mg [I1065] Isoflavonoids Kaempferide 10mg / 50mg [K0057] Kaempferol Hydrate 100mg / 1g [K0018] Biochanin A 200mg / 1g / 5g [B4098] Luteolin 1g / 5g [T2682] Daidzein 1g [D2668] Methyl Hesperidine 5g / 25g [M0338] Daidzin 25mg [D3920] 6-Methoxyflavanone 1g / 5g [M1403] Dihydrodaidzein 25mg [D4239] 6-Methoxyflavone 1g / 5g [M1346] (±)-Equol 200mg [E0922] 7-Methoxyflavone 1g / 5g [M1423] Formononetin 1g / 5g [F0868] Morin Hydrate 1g / 5g / 25g [P0041] Genistein 100mg / 1g [G0272] Myricetin 500mg / 5g [M2131] Ipriflavone 5g / 25g [I0669] Myricitrin 10mg / 50mg [M2361] Ononin 10mg [O0405] 3-Methoxyflavone 1g / 5g [M2364] Puerarin 200mg / 1g [P1886] 5-Methoxyflavone 1g / 5g [M2365] Rotenone 5g / 25g [R0090] Naringenin 5g / 25g [N0072] Catechins Naringin Hydrate 25g [N0073] Neohesperidin 100mg [N1121] (+)-Catechin Hydrate 1g / 10g [C0705] Quercetin Hydrate 25g [P0042] (-)-Epicatechin 1g / 5g [E1226] Rutin Hydrate 25g [R0035] (-)-Epicatechin Gallate 20mg / 100mg [E0890] Silybin (mixture of Silybin A and Silybin B) 5g / 25g [S0508] (-)-Epigallocatechin 10mg / 50mg [E1084] Tangeretin 10mg / 100mg [T2708] (-)-Epigallocatechin Gallate Hydrate 100mg / 500mg [E0694] Wogonin 50mg / 250mg [W0010] Polyphenols Chalconoids Diarylheptanoids Butein 100mg / 1g [B3803] Bisdemethoxycurcumin 5g / 25g [B3347] Chalcone 25g / 100g / 500g [C0071] Curcumin (Natural) 1g / 25g [C0434] 2-Hydroxychalcone 5g / 25g [H0234] Curcumin (Synthetic) 5g / 25g [C2302] 2'-Hydroxychalcone 25g [H0385] 4'-Hydroxychalcone 5g [H0945] Phenylpropanoids 4-Hydroxychalcone 5g [H0955] 2-Acetoxycinnamic Acid 1g / 5g [A2413] Isoliquiritigenin 100mg / 1g [I0822] 4-Methoxychalcone 25g [M1409] Acetylisoeugenol 25g / 500g [A1184] Neohesperidin Dihydrochalcone Hydrate 5g / 25g [N0675] 4-Aminocinnamic Acid 5g / 25g [A0691] Phlorizin Hydrate 1g / 5g [P0248] trans-Anethole 25g / 100g / 500g [P0494] Phloretin 1g / 5g [P1966] Caffeic Acid 5g / 25g [C0002] Xanthohumol 25mg [X0068] Caffeic Acid Methyl Ester 200mg / 1g [M2519] Caffeic Acid Phenethyl Ester 25mg / 250mg [P2088] Chlorogenic Acid Hydrate 1g / 5g [C0181] Coumarins Cholesterol trans-Cinnamate 25g [C0617] 7-Acetoxy-4-methylcoumarin 5g [A1527] α-CHCA 1g [C1768] 8-Acetyl-7-hydroxy-4-methylcoumarin 5g [A1848] Cinnamyl Acetate 25mL / 500mL [A0901] 3-Acetylcoumarin 5g / 25g [A2200] Cinnamyl Cinnamate 25g [C0960] Angelicin 25mg [A2573] trans-Cinnamaldehyde 25mL / 500mL [C0352] 1g / 5g [B2840] Bergapten trans-Cinnamic Acid 25g / 100g / 500g [C0353] Columbianadin 25mg / 100mg [C3479] trans-p-Coumaric Acid 25g / 100g / 500g [C0393] Coumarin 25g / 500g [C0395] 100mg / 1g Daphnetin 1g / 5g [D4001] Dienestrol Diacetate [B1366] Dicoumarol 1g / 25g [M0216] 2,4-Dimethoxycinnamic Acid 25g [D2364] 6,7-Dihydroxycoumarin-3-carboxylic Acid 1g / 5g [D4170] 2,5-Dimethoxycinnamic Acid 10g [D1972] Ellagic Acid Dihydrate 5g / 25g [E0375] 3,4-Dimethoxycinnamic Acid 25g [D1728] Esculin Sesquihydrate 5g / 25g [E0024] trans-2,3-Dimethoxycinnamic Acid 25g [D2326] Esculetin 1g [E0386] Estragole 10g / 100g [A0702] 7-Ethoxy-4-methylcoumarin 25g [E0491] Eugenol 25mL / 100mL / 500mL [A0232] 4-Ethoxycoumarin 5g / 25g [E0545] Eugenol Acetate 25g [E0210] 7-Ethoxycoumarin 5g / 25g [E0538] Eugenol Methyl Ether 25mL / 500mL [D1360] 25g / 100g / 250g 4-Hydroxycoumarin [H0235] trans-Ferulic Acid 25g / 100g / 250g [H0267] 6-Hydroxy-4-methylcoumarin 5g / 25g [H1005] [6]-Gingerol 20mg [G0413] Isopimpinellin 10mg [I0861] 7-Methoxy-4-methylcoumarin 5g [M1393] Honokiol 200mg / 1g [H1309] 7-Methoxycoumarin 5g / 25g [M1723] Isoeugenol (cis- and trans- mixture) 25g / 100g / 500g [I0132] 4-Methylcoumarin 1g [M3041] Magnolol 200mg / 1g [D3971] 6-Methylcoumarin 25g [M0189] 4-Methoxycinnamic Acid 25g / 100g [M0576] 7-Methylcoumarin 25g [M1236] O-Methyl Isoeugenol 25mL / 100mL / 500mL [P1103] 4-Methylesculetin 25g [M0766] γ-Oryzanol 25g / 250g [O0172] 4-Methylumbelliferone 25g / 100g / 500g [M0453] 2-Phenylethyl Cinnamate 25g / 500g [P2007] 4-Methylumbelliferyl Phosphate 100mg [P1060] Propenylguaethol 25g / 100g [E0804] 6-Nitrocoumarin 5g / 25g [N0923] Rhododendrol 1g [R0121] 250mg / 1g / 5g Osthole [O0426] Sinapinic Acid 5g / 25g [D1765] Psoralen 20mg / 100mg [P2077] 2,3,4-Trimethoxycinnamic Acid 5g / 25g [T2016] Psoralidin 25mg / 100mg [P2605] Scopoletin 100mg / 1g [S0367] 2,4,5-Trimethoxycinnamic Acid 5g [T1393] Trioxsalen 1g / 5g [T2267] 3,4,5-Trimethoxycinnamic Acid 25g [T1104] Umbelliferone 5g / 25g [H0236] Zingerone 25g / 100g [H1314] Warfarin Sodium 5g / 25g [W0005] Xanthotoxin 100mg / 1g [X0009] For Laboratory Use, Research Purposes Only. polyphenol For further information please refer to our website at www.TCIchemicals.com. ▼ ▼ ▼ Ordering and Tel : +32 (0)3 735 07 00 Tel : +44 (0)1865 78 45 60 Tel : 800-988-0390 / 021-67121386 Customer Service Fax : +32 (0)3 735 07 01 E-mail : [email protected] Fax : 021-6712-1385 E-mail : [email protected] E-mail : [email protected] Tel : 800-423-8616 / 503-283-1681 Tel : +49 (0)6196 64053-00 Tel : 1800 425 7889 / 044-2262 0909 Tel : +81 (0)3-5640-8878 Fax : 888-520-1075 / 503-283-1987 Fax : +49 (0)6196 64053-01 Fax : 044-2262 8902 E-mail : [email protected] E-mail : [email protected] E-mail : [email protected] E-mail : [email protected] Availability, price or specification of the listed products are subject to change without prior notice. Reproduction forbidden without the prior written consent of Tokyo Chemical Industry Co., Ltd. www.TCIchemicals.com LL011E 20210907.
Load more

Recommended publications
  • Natural Products As Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
    Reviews Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors Author ABSTRACT Wolfgang Blaschek Glucose homeostasis is maintained by antagonistic hormones such as insulin and glucagon as well as by regulation of glu- Affiliation cose absorption, gluconeogenesis, biosynthesis and mobiliza- Formerly: Institute of Pharmacy, Department of Pharmaceu- tion of glycogen, glucose consumption in all tissues and glo- tical Biology, Christian-Albrechts-University of Kiel, Kiel, merular filtration, and reabsorption of glucose in the kidneys. Germany Glucose enters or leaves cells mainly with the help of two membrane integrated transporters belonging either to the Key words family of facilitative glucose transporters (GLUTs) or to the Malus domestica, Rosaceae, Phlorizin, flavonoids, family of sodium glucose cotransporters (SGLTs). The intesti- ‑ SGLT inhibitors, gliflozins, diabetes nal glucose absorption by endothelial cells is managed by SGLT1, the transfer from them to the blood by GLUT2. In the received February 9, 2017 kidney SGLT2 and SGLT1 are responsible for reabsorption of revised March 3, 2017 filtered glucose from the primary urine, and GLUT2 and accepted March 6, 2017 GLUT1 enable the transport of glucose from epithelial cells Bibliography back into the blood stream. DOI http://dx.doi.org/10.1055/s-0043-106050 The flavonoid phlorizin was isolated from the bark of apple Published online April 10, 2017 | Planta Med 2017; 83: 985– trees and shown to cause glucosuria. Phlorizin is an inhibitor 993 © Georg Thieme Verlag KG Stuttgart · New York | of SGLT1 and SGLT2. With phlorizin as lead compound, specif- ISSN 0032‑0943 ic inhibitors of SGLT2 were developed in the last decade and some of them have been approved for treatment mainly of Correspondence type 2 diabetes.
    [Show full text]
  • Myricetin Antagonizes Semen-Derived Enhancer of Viral Infection (SEVI
    Ren et al. Retrovirology (2018) 15:49 https://doi.org/10.1186/s12977-018-0432-3 Retrovirology RESEARCH Open Access Myricetin antagonizes semen‑derived enhancer of viral infection (SEVI) formation and infuences its infection‑enhancing activity Ruxia Ren1,2†, Shuwen Yin1†, Baolong Lai2, Lingzhen Ma1, Jiayong Wen1, Xuanxuan Zhang1, Fangyuan Lai1, Shuwen Liu1* and Lin Li1* Abstract Background: Semen is a critical vector for human immunodefciency virus (HIV) sexual transmission and harbors seminal amyloid fbrils that can markedly enhance HIV infection. Semen-derived enhancer of viral infection (SEVI) is one of the best-characterized seminal amyloid fbrils. Due to their highly cationic properties, SEVI fbrils can capture HIV virions, increase viral attachment to target cells, and augment viral fusion. Some studies have reported that myri- cetin antagonizes amyloid β-protein (Aβ) formation; myricetin also displays strong anti-HIV activity in vitro. Results: Here, we report that myricetin inhibits the formation of SEVI fbrils by binding to the amyloidogenic region of the SEVI precursor peptide (PAP248–286) and disrupting PAP248–286 oligomerization. In addition, myricetin was found to remodel preformed SEVI fbrils and to infuence the activity of SEVI in promoting HIV-1 infection. Moreover, myricetin showed synergistic efects against HIV-1 infection in combination with other antiretroviral drugs in semen. Conclusions: Incorporation of myricetin into a combination bifunctional microbicide with both anti-SEVI and anti- HIV activities is a highly promising approach to preventing sexual transmission of HIV. Keywords: HIV, Myricetin, Amyloid fbrils, SEVI, Synergistic antiviral efects Background in vivo because they facilitate virus attachment and inter- Since the frst cases of acquired immune defciency nalization into cells [4].
    [Show full text]
  • Ipriflavone in the Treatment of Postmenopausal Osteoporosis a Randomized Controlled Trial
    ORIGINAL CONTRIBUTION Ipriflavone in the Treatment of Postmenopausal Osteoporosis A Randomized Controlled Trial Peter Alexandersen, MD Context Data on the efficacy and safety of ipriflavone for prevention of postmeno- Anne Toussaint, MD pausal bone loss are conflicting. Claus Christiansen, MD, PhD Objectives To investigate the effect of oral ipriflavone on prevention of postmeno- pausal bone loss and to assess the safety profile of long-term treatment with iprifla- Jean-Pierre Devogelaer, MD, PhD vone in postmenopausal osteoporotic women. Christian Roux, MD, PhD Design and Setting Prospective, randomized, double-blind, placebo-controlled, 4-year Jacques Fechtenbaum, MD, PhD study conducted in 4 centers in Belgium, Denmark, and Italy from August 1994 to July 1998. Carlo Gennari, MD, PhD Participants Four hundred seventy-four postmenopausal white women, aged 45 Jean Yves Reginster, MD, PhD to 75 years, with bone mineral densities (BMDs) of less than 0.86 g/cm2. for the Ipriflavone Multicenter Interventions Patients were randomly assigned to receive ipriflavone, 200 mg 3 times European Fracture Study per day (n = 234), or placebo (n = 240); all received 500 mg/d of calcium. TUDIES OF IPRIFLAVONE, A SYN- Main Outcome Measures Efficacy measures included spine, hip, and forearm BMD thetic isoflavone derivative, have and biochemical markers of bone resorption (urinary hydroxyproline corrected for cre- atinine and urinary CrossLaps [Osteometer Biotech, Herlev, Denmark] corrected for suggested that it inhibits bone re- creatinine), assessed every 6 months. Laboratory safety measures and adverse events sorption and stimulates osteo- were recorded every 3 months. Sblast activity in vitro in cell cultures1,2 and Results Based on intent-to-treat analysis, after 36 months of treatment, the annual in vivo in experimental models of osteo- 3 percentage change from baseline in BMD of the lumbar spine for ipriflavone vs pla- porosis.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Botanicals in Postmenopausal Osteoporosis
    nutrients Review Botanicals in Postmenopausal Osteoporosis Wojciech Słupski, Paulina Jawie ´nand Beata Nowak * Department of Pharmacology, Wroclaw Medical University, ul. J. Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland; [email protected] (W.S.); [email protected] (P.J.) * Correspondence: [email protected]; Tel.: +48-607-924-471 Abstract: Osteoporosis is a systemic bone disease characterized by reduced bone mass and the deterioration of bone microarchitecture leading to bone fragility and an increased risk of fractures. Conventional anti-osteoporotic pharmaceutics are effective in the treatment and prophylaxis of osteoporosis, however they are associated with various side effects that push many women into seeking botanicals as an alternative therapy. Traditional folk medicine is a rich source of bioactive compounds waiting for discovery and investigation that might be used in those patients, and therefore botanicals have recently received increasing attention. The aim of this review of literature is to present the comprehensive information about plant-derived compounds that might be used to maintain bone health in perimenopausal and postmenopausal females. Keywords: osteoporosis; menopause; botanicals; herbs 1. Introduction Women’s health and quality of life is modulated and affected strongly by hormone status. An oestrogen level that changes dramatically throughout life determines the Citation: Słupski, W.; Jawie´n,P.; development of women’s age-associated diseases. Age-associated hormonal imbalance Nowak, B. Botanicals in and oestrogen deficiency are involved in the pathogenesis of various diseases, e.g., obesity, Postmenopausal Osteoporosis. autoimmune disease and osteoporosis. Many female patients look for natural biological Nutrients 2021, 13, 1609. https:// products deeply rooted in folk medicine as an alternative to conventional pharmaceutics doi.org/10.3390/nu13051609 used as the prophylaxis of perimenopausal health disturbances.
    [Show full text]
  • Defective Galactose Oxidation in a Patient with Glycogen Storage Disease and Fanconi Syndrome
    Pediatr. Res. 17: 157-161 (1983) Defective Galactose Oxidation in a Patient with Glycogen Storage Disease and Fanconi Syndrome M. BRIVET,"" N. MOATTI, A. CORRIAT, A. LEMONNIER, AND M. ODIEVRE Laboratoire Central de Biochimie du Centre Hospitalier de Bichre, 94270 Kremlin-Bicetre, France [M. B., A. C.]; Faculte des Sciences Pharmaceutiques et Biologiques de I'Universite Paris-Sud, 92290 Chatenay-Malabry, France [N. M., A. L.]; and Faculte de Midecine de I'Universiti Paris-Sud et Unite de Recherches d'Hepatologie Infantile, INSERM U 56, 94270 Kremlin-Bicetre. France [M. 0.1 Summary The patient's diet was supplemented with 25-OH-cholecalci- ferol, phosphorus, calcium, and bicarbonate. With this treatment, Carbohydrate metabolism was studied in a child with atypical the serum phosphate concentration increased, but remained be- glycogen storage disease and Fanconi syndrome. Massive gluco- tween 0.8 and 1.0 mmole/liter, whereas the plasma carbon dioxide suria, partial resistance to glucagon and abnormal responses to level returned to normal (18-22 mmole/liter). Rickets was only carbohydrate loads, mainly in the form of major impairment of partially controlled. galactose utilization were found, as reported in previous cases. Increased blood lactate to pyruvate ratios, observed in a few cases of idiopathic Fanconi syndrome, were not present. [l-14ClGalac- METHODS tose oxidation was normal in erythrocytes, but reduced in fresh All studies of the patient and of the subjects who served as minced liver tissue, despite normal activities of hepatic galactoki- controls were undertaken after obtaining parental or personal nase, uridyltransferase, and UDP-glucose 4epirnerase in hornog- consent. enates of frozen liver.
    [Show full text]
  • Nutriceuticals: Over-The-Counter Products and Osteoporosis
    serum calcium levels are too low, and adequate calcium is not provided by the diet, calcium is taken from bone. Osteoporosis: Clinical Updates Long- term dietary calcium deficiency is a known risk Osteoporosis Clinical Updates is a publication of the National factor for osteo porosis. The recommended daily cal- Osteoporosis Foundation (NOF). Use and reproduction of this publication for educational purposes is permitted and cium intake from diet and supplements combined is encouraged without permission, with proper citation. This 1000 mg/day for people aged 19 to 50 and 1200 mg/ publication may not be used for commercial gain. NOF is a day for people older than 50. For all ages, the tolerable non-profit, 501(c)(3) educational organization. Suggested upper limit is 2500 mg calcium per day. citation: National Osteoporosis Foundation. Osteoporosis Clinical Updates. Issue Title. Washington, DC; Year. Adequate calcium intake is necessary for attaining peak bone mass in early life (until about age 30) and for Please direct all inquiries to: National Osteoporosis slowing the rate of bone loss in later life.3 Although Foundation 1150 17th Street NW Washington, DC 20037, calcium alone (or with vitamin D) has not been shown USA Phone: 1 (202) 223-2226 to prevent estrogen-related bone loss, multiple stud- Fax: 1 (202) 223-1726 www.nof.org ies have found calcium consumption between 650 mg Statement of Educational Purpose and over 1400 mg/day reduces bone loss and increases Osteoporosis Clinical Updates is published to improve lumbar spine BMD.4-6 osteoporosis patient care by providing clinicians with state-of-the-art information and pragmatic strategies on How to take calcium supplements: prevention, diagnosis, and treatment that they may apply in Take calcium supplements with food.
    [Show full text]
  • List of Compounds 2018 年12 月
    List of Compounds 2018 年12 月 長良サイエンス株式会社 Nagara Science Co., Ltd. 〒501-1121 岐阜市古市場 840 840 Furuichiba, Gifu 501-1121, JAPAN Phone : +81-58-234-4257、Fax : +81-58-234-4724 E-mail : [email protected] 、http : //www.nsgifu.jp Storage Product Name・Purity・Molecular Formula＝Molecular Weight・〔 CAS Quantity Source Code No. C o n di t i o n s Registry Number 〕 ・Price ( JPY ) NH020102 2－10 ℃ (-)-Epicatechin [ (-)-EC ] ≧99% (HPLC) 10mg 8,000 NH020103 C15H14O6 = 290.27 〔490-46-0〕 100mg 44,000 NH020202 2－10 ℃ (-)-Epigallocatechin [ (-)-EGC ] ≧99% (HPLC) 10mg 12,000 NH020203 C15H14O7 = 306.27 〔970-74-1〕 100mg 66,000 NH020302 2－10 ℃ (-)-Epicatechin gallate [ (-)-ECg ] ≧99% (HPLC) 10mg 12,000 NH020303 C22H18O10 = 442.37 〔1257-08-5〕 100mg 52,000 NH020403 2－10 ℃ (-)-Epigallocatechin gallate [ (-)-EGCg ] ≧98% (HPLC) 100mg 12,000 〔 〕 C22H18O11 = 458.37 989-51-5 NH020602 2－10 ℃ (-)-Epigallocatechin gallate [ (-)-EGCg ] ≧99% (HPLC) 20mg 12,000 NH020603 C22H18O11 = 458.37 〔989-51-5〕 100mg 30,000 NH020502 2－10 ℃ (+)-Catechin hydrate [ (+)-C ] ≧99% (HPLC) 10mg 5,000 NH020503 C15H14O6 ･H2O = 308.28 〔88191-48-4〕 100mg 32,000 NH021102 2－10 ℃ (-)-Catechin [ (-)-C ] ≧98% (HPLC) 10mg 23,000 C15H14O6 = 290.27 〔18829-70-4〕 NH021202 2－10 ℃ (-)-Gallocatechin [ (-)-GC ] ≧98% (HPLC) 10mg 34,000 〔 〕 C15H14O7 = 306.27 3371-27-5 NH021302 － ℃ ≧ 10mg 34,000 2 10 (-)-Catechin gallate [ (-)-Cg ] 98% (HPLC) C22H18O10 = 442.37 〔130405-40-2〕 NH021402 2－10 ℃ (-)-Gallocatechin gallate [ (-)-GCg ] ≧98% (HPLC) 10mg 23,000 C22H18O11 = 458.37 〔4233-96-9〕 NH021502 2－10 ℃ (+)-Epicatechin [ (+)-EC
    [Show full text]
  • Applications of Mass Spectrometry in Natural Product Drug Discovery for Malaria: Targeting Plasmodium Falciparum Thioredoxin Reductase
    Applications of mass spectrometry in natural product drug discovery for malaria: Targeting Plasmodium falciparum thioredoxin reductase by Ranjith K. Munigunti A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy Auburn, Alabama May 5, 2013 Keywords: Chromatography, mass spectrometry, malaria, Plasmodium falciparum, thioredoxin reductase, thioredoxin Copyright 2013 by Ranjith K. Munigunti Approved by Angela I. Calderón, Chair, Assistant Professor of Pharmacal Sciences C. Randall Clark, Professor of Pharmacal Sciences Jack DeRuiter, Professor of Pharmacal Sciences Forrest Smith, Associate Professor of Pharmacal Sciences Orlando Acevedo, Associate Professor of Chemistry and Biochemistry Abstract Malaria is considered to be the dominant cause of death in low income countries especially in Africa. Malaria caused by Plasmodium falciparum is a most lethal form of the disease because of its rapid spread and the development of drug resistance. The main problem in the treatment of malaria is the emergence of drug resistant malaria parasites. Over the years/decades, natural products have been used for the treatment or prevention of number of diseases. They can serve as compounds of interest both in their natural form and as templates for synthetic modification. Nature has provided a wide variety of compounds that inspired the development of potential therapeutics such as quinine, artemisinin and lapachol as antimalarial agents. As the resistance to known antimalarials is increasing, there is a need to expand the antimalarial drug discovery efforts for new classes of molecules to combat malaria. This research work focuses on the applications of ultrafiltration, mass spectrometry and molecular modeling based approaches to identify inhibitors of Plasmodium falciparum thioredoxin reductase (PfTrxR), our main target and Plasmodium falciparum glutathione reductase (PfGR) as an alternative target for malaria drug discovery.
    [Show full text]
  • Ipriflavone: an Important Bone-Building Isoflavone
    Ipriflavone: An Important Bone-Building Isoflavone Kathleen A. Head, N.D. Abstract Ipriflavone, an isoflavone synthesized from the soy isoflavone daidzein, holds great promise in the prevention and treatment of osteoporosis and other metabolic bone diseases. It has been widely studied in humans and found effective for inhibiting bone resorption and enhancing bone formation, the net result being an increase in bone density and a decrease in fracture rates in osteoporotic women. While ipriflavone appears to enhance estrogen’s effect, it does not possess intrinsic estrogenic activity, making it an attractive adjunct or alternative to conventional hormone replacement therapy. Preliminary studies have also found ipriflavone effective in preventing bone loss associated with chronic steroid use, immobility, ovariectomy, renal osteodystro- phy, and gonadotrophin hormone-releasing hormone agonists. In addition, it holds prom- ise for the treatment of other metabolic diseases affecting the bones, including Paget’s disease of the bone, hyperparathyroidism, and tinnitus caused by otosclerosis. (Altern Med Rev 1999;4(1):10-22) Introduction Ipriflavone (chemical structure: 7-isopropoxyisoflavone), derived from the soy isoflavone, daidzein, holds great promise for osteoporosis prevention and treatment (see Figure 1). Ipriflavone (IP) was discovered in the 1930s but has only recently begun to be embraced by the medical community in this country. Over 150 studies on safety and effective- ness, both animal and human, have been conducted in Italy, Hungary, and Japan. As of 1997, 2,769 patients had been treated a total of 3,132 patient years.1 Pharmacokinetics IP is metabolized mainly in the liver and excreted in the urine. Food appears to enhance its absorption.
    [Show full text]
  • Oxyresveratrol의 기원, 생합성, 생물학적 활성 및 약물동력학
    KOREAN J. FOOD SCI. TECHNOL. Vol. 47, No. 5, pp. 545~555 (2015) http://dx.doi.org/10.9721/KJFST.2015.47.5.545 총설 ©The Korean Society of Food Science and Technology Oxyresveratrol의 기원, 생합성, 생물학적 활성 및 약물동력학 임영희·김기현 1·김정근 1,* 고려대학교 보건과학대학 바이오시스템의과학부, 1한국산업기술대학교 생명화학공학과 Source, Biosynthesis, Biological Activities and Pharmacokinetics of Oxyresveratrol 1 1, Young-Hee Lim, Ki-Hyun Kim , and Jeong-Keun Kim * School of Biosystem and Biomedical Science, Korea University 1Department of Chemical Engineering and Biotechnology, Korea Polytechnic University Abstract Oxyresveratrol (trans-2,3',4,5'-tetrahydroxystilbene) has been receiving increasing attention because of its astonishing biological activities, including antihyperlipidemic, neuroprotection, antidiabetic, anticancer, antiinflammation, immunomodulation, antiaging, and antioxidant activities. Oxyresveratrol is a stilbenoid, a type of natural phenol and a phytoalexin produced in the roots, stems, leaves, and fruits of several plants. It was first isolated from the heartwood of Artocarpus lakoocha, and has also been found in various plants, including Smilax china, Morus alba, Varatrum nigrum, Scirpus maritinus, and Maclura pomifera. Oxyresveratrol, an aglycone of mulberroside A, has been produced by microbial biotransformation or enzymatic hydrolysis of a glycosylated stilbene mulberroside A, which is one of the major compounds of the roots of M. alba. Oxyresveratrol shows less cytotoxicity, better antioxidant activity and polarity, and higher cell permeability and bioavailability than resveratrol (trans-3,5,4'-trihydroxystilbene), a well-known antioxidant, suggesting that oxyresveratrol might be a potential candidate for use in health functional food and medicine. This review focuses on the plant sources, chemical characteristics, analysis, biosynthesis, and biological activities of oxyresveratrol as well as describes the perspectives on further exploration of oxyresveratrol.
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative
    Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Sedative Chemical Dosage (+)-BORNYL-ISOVALERATE -- (-)-DICENTRINE LD50=187 1,8-CINEOLE -- 2-METHYLBUT-3-ENE-2-OL -- 6-GINGEROL -- 6-SHOGAOL -- ACYLSPINOSIN -- ADENOSINE -- AKUAMMIDINE -- ALPHA-PINENE -- ALPHA-TERPINEOL -- AMYL-BUTYRATE -- AMYLASE -- ANEMONIN -- ANGELIC-ACID -- ANGELICIN ED=20-80 ANISATIN 0.03 mg/kg ANNOMONTINE -- APIGENIN 30-100 mg/kg ARECOLINE 1 mg/kg ASARONE -- ASCARIDOLE -- ATHEROSPERMINE -- BAICALIN -- BALDRINAL -- BENZALDEHYDE -- BENZYL-ALCOHOL -- Chemical Dosage BERBERASTINE -- BERBERINE -- BERGENIN -- BETA-AMYRIN-PALMITATE -- BETA-EUDESMOL -- BETA-PHENYLETHANOL -- BETA-RESERCYCLIC-ACID -- BORNEOL -- BORNYL-ACETATE -- BOSWELLIC-ACID 20-55 mg/kg ipr rat BRAHMINOSIDE -- BRAHMOSIDE -- BULBOCAPNINE -- BUTYL-PHTHALIDE -- CAFFEIC-ACID 500 mg CANNABIDIOLIC-ACID -- CANNABINOL ED=200 CARPACIN -- CARVONE -- CARYOPHYLLENE -- CHELIDONINE -- CHIKUSETSUSAPONIN -- CINNAMALDEHYDE -- CITRAL ED 1-32 mg/kg CITRAL 1 mg/kg CITRONELLAL ED=1 mg/kg CITRONELLOL -- 2 Chemical Dosage CODEINE -- COLUBRIN -- COLUBRINOSIDE -- CORYDINE -- CORYNANTHEINE -- COUMARIN -- CRYOGENINE -- CRYPTOCARYALACTONE 250 mg/kg CUMINALDEHYDE -- CUSSONOSIDE-A -- CYCLOSTACHINE-A -- DAIGREMONTIANIN -- DELTA-9-THC 10 mg/orl/man/day DESERPIDINE -- DESMETHOXYANGONIN 200 mg/kg ipr DIAZEPAM 40-200 ug/lg/3-4x/day DICENTRINE LD50=187 DIDROVALTRATUM -- DIHYDROKAWAIN -- DIHYDROMETHYSTICIN 60 mg/kg ipr DIHYDROVALTRATE -- DILLAPIOL ED50=1.57 DIMETHOXYALLYLBENZENE -- DIMETHYLVINYLCARBINOL -- DIPENTENE
    [Show full text]